Business Wire

TX-MARY-KAY

12.1.2023 22:22:41 CET | Business Wire | Press release

Share
Mary Kay Inc. Company-Sponsored Foundations Give Millions Supporting Women's Causes Around the World

Throughout 2022, iconic beauty brand Mary Kay—along with its company-sponsored foundations—gave more than 3 million dollars to support women’s causes around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005756/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Female entrepreneurs in Chuxiong, Yunnan Province increased their income and helped preserve the Yunnan Embroidery cultural industry thanks to Mary Kay Women’s Entrepreneurship Program. (Photo: Mary Kay Inc.)

When Mary Kay Ash, legendary businesswoman and philanthropist, opened her business in 1963, she dreamed of empowering women internationally through entrepreneurship, innovation, hard work, and giving back. Nearly 60 years later, Mary Kay employees, Independent Beauty Consultants, and members of the global community keep her dream alive through generous contributions to four company-sponsored foundations delivering impactful support to women and their families in need.

The full foundation reports can be viewed here. Here’s what they were up to in 2022:

Cancers Affecting Women

  • In the U.S., the Mary Kay Ash Foundation (MKAF) funded 37 cancer researchers conducting groundbreaking research against cancers affecting women.
  • 43% of MKAF cancer research projects are led by women; 100% of clinical trials are women-led.
  • MKAF funded nearly $1.7 million in grants for cancers affecting women.

Gender-based Violence

  • MKAF funded nearly $1.4 million in grants supporting services for women survivors of domestic violence.
  • MKAF supported 4 local domestic violence shelters in North Texas providing women seeking help with vital resources and safety.
  • In collaboration with Mary Kay, MKAF supported global partners committed to end violence against women and girls, including CARE and UN Trust Fund. Together, MKAF partners completed over 550 projects around the world.
  • Instituto Mary Kay and Mary Kay Brazil received the Silver Award for the Red Cross Campaign “Campanha Sinal Vermelho Contra a Violência Doméstica” at ABEVD Associação Brasileira das Empresas de Venda Direta (Brazil DSA) Anual Congress.
  • In Canada, the Mary Kay Ash Charitable Foundation awarded $10,000 each to 16 domestic violence shelters across Canada, totaling $160,000.

Women and Their Families

Mary Kay China and its company-sponsored programs and fund have provided support through the following efforts:

  • Mary Kay Women’s Entrepreneurship Program
    • In cooperation with China Women’s Development Foundation, interest-free revolving loans were provided to four women entrepreneur initiatives in the provinces of Heilongjiang, Ningxia, and Jilin. The initiatives directly benefited 133 women by increasing their annual per capita income by RMB 20,000 yuan.

  • Young Women’s Future Fund
    • In cooperation with Adream Foundation, the Young Women’s Future Fund remaining balance will be used to build four Mary Kay Dream Classrooms in Jiangxi to enhance girls’ literacy education.

  • Mary Kay China Charity Program
    • Since March 2022, the Mary Kay China Charity Program has allocated 1,049,800 yuan to provide protective materials and living supplies to 73 communities in 15 cities as a result of the COVID-19 epidemic.
    • Thanks to the joint efforts of Mary Kay China and its Beauty Consultants, the "Smile 1000" project raised funds for 112 cleft-lip repair surgeries in 2022. To date, Mary Kay China has raised funds for 991 surgeries and is on track to achieve the goal of 1,000 smiles in 2023.
    • By May, 1,391 Beauty Consultant volunteers had delivered 331 beauty lessons to 9,147 women.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005756/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye